Abstract: A method for inducing differentiation into pancreatic ? cells includes: a step (a) of culturing endodermal cells, which have been induced to differentiate from pluripotent stem cells, in the presence of a bone morphogenetic protein (BMP) signaling inhibitor, and retinoic acid or a retinoic acid analog to induce differentiation into primitive gut tube (PGT) cells; a step (b) of culturing the primitive gut tube (PGT) cells to induce differentiation into pancreatic endocrine precursor (EP) cells; and a step (c) of culturing the pancreatic endocrine precursor (EP) cells to induce differentiation into pancreatic ? cells, in which the step (b) and the step (c) are performed in the absence of ascorbic acid.

Abstract: Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.

Abstract: Described herein are methods and compositions for use in improving a vascular barrier of endothelial cells. The methods may include the use of barrier agonist compounds and improved techniques for culturing endothelial cells. The improved methods and compositions for culturing endothelial cells may include at least one or more of the following: an adenylyl cyclase activator; an activator of Sphingosine-1-phosphate (S1P) receptor internalization; a direct or indirect inducer of tight junction protein expression, and a direct or indirect inducer of adherens junction protein expression.

Abstract: The present invention relates to endothelial cells and methods of generating endothelial cells from pluripotent stem cells.

Abstract: Provided are methods and compositions for tissue engineering including methods and compositions for the generation of vascularized organoids in vitro.

Abstract: The present invention relates to a kidney organoid having a nephron-like structure and a production method therefor. A kidney organoid culture system using kidney dECM hydrogels according to the present invention induced the vascularization of the kidney organoid and the expression of podocytes, tubular transporters, and cilium genes, and has an effect of forming a more mature nephron-like structure. Therefore, the kidney organoid produced by the method of the present invention is an option for treating nephron loss through transplantation into humans, and is expected to be utilized as a kidney on a chip, which is an in vitro kidney model.

Abstract: The present invention relates to transgenic grape cells, compositions comprising such cells or extracts or fractions thereof, and methods of use thereof for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject. Disclosed herein are also methods for preventing, treating, reducing the incidence, suppressing or inhibiting a coronavirus infection or a symptom thereof.

Abstract: A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

Abstract: Method for producing a defective interfering viral genome (DVG), defective interfering particles comprising the DVG, and methods and uses thereof.

Abstract: The present disclosure relates to bacteriophage and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.

Abstract: The disclosure herein provides a monomeric prolyl 4-hydroxylase. A microorganism including a monomeric prolyl 4-hydroxylase is provided. The disclosure provides a microorganism including a monomeric prolyl 4-hydroxylase; and another protein to be hydroxylated. A method for providing skincare benefits including applying the fusion protein of the present disclosure on skin is also taught.

Abstract: The present invention relates to a method of preparing a gene cluster construct including a plurality of genes encoding a multi-modular biosynthetic enzyme, the method including (A) a step of preparing a plurality of DNA fragments which are capable of reconstructing the gene cluster construct and have structures that can be ligated to each other and (B) a step of ligating the plurality of DNA fragments prepared in the step (A) to each other by mixing the plurality of DNA fragments in a solution to obtain the gene cluster construct.

Abstract: This application relates to mutant polymerases. This application discloses mutant phage-type RNA polymerases, such as a mutant T7, SP6, and T3 RNA polymerase, may use 2?-modified nucleoside triphosphates or deoxynucleotide triphosphates as substrates. Methods for producing nucleic acid molecules using these mutant polymerases are also disclosed.

Abstract: The disclosure relates to methods and compositions for inhibiting the expression of the DUX4 gene in skeletal muscle cells. In some aspects, the invention includes a CRISPR interference platform that directs an epigenetic regulator to the DUX4 locus. In some aspects, methods described by the disclosure are useful in modulating DUX4 expression for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Abstract: The present invention provides: a complex comprising a genome editing enzyme and a cell membrane-permeable peptide(CPP), wherein the CPP is fused to the genome editing enzyme; a complex comprising a genome editing enzyme, a target gene-specific nucleic acid, and a CPP, wherein the CPP is fused to the genome editing enzyme and/or the a target gene-specific nucleic acid; the complex comprising a polycationic moiety fused to the CPP, wherein the polycation moiety is statically bound to the target gene-specific nucleic acid; a genome editing method using the complex; and a kit for genome-editing, the kit including these complexes.

Abstract: The present invention relates to a fusion protein comprising a domain of a nuclease from the class II CRISPR system, and a Spo11 domain, wherein both domains of the fusion protein have deficient nuclease activity, as well as the use of this protein to induce targeted meiotic recombinations in a eukaryotic cell.

Abstract: The present disclosure relates to automated multi-module instruments, compositions and methods for performing nucleic acid-guided nuclease editing; specifically, the disclosure provides nucleic acid cassettes, plasmids, vectors, and compositions comprising the same that employ homologous recombination for genome engineering by having a CRISPR nuclease cause a specific DSB while tethered to a repair nucleic acid.

Abstract: Disclosed are compositions and methods relating to variant ?-amylases. The variant ?-amylases are useful, for example, for starch liquefaction and saccharification, cleaning starchy stains, textile desizing, baking and brewing.

Abstract: Disclosed is a method for producing hyaluronidase or a variant thereof. Specifically, the method is capable of changing the N-glycan levels under culture conditions including a controlled concentration of glucose in the culture medium and a decreased culture temperature for a specific culture time period, thereby increasing the specific activity by 10% or more and improving the quality and production yield.

Abstract: The present disclosure relates to a novel serine protease variant.

Abstract: A method of producing a biofilm-like microorganism-polymer complex, the method comprising the step of exposing, in an aqueous medium, cells of a microorganism to a polymer comprising groups as defined by formula (la) or formula (lb), wherein: Y comprises an imine; and R2 comprises a CI-30 group. A biofilm-like microorganism-polymer complex comprising cells of a microorganism and a polymer comprising groups as defined by formula (la) and/or formula (lb). A method for producing a chemical and/or biological product using the microorganism-polymer complex, and the chemical and/or biological products obtained therefrom. A method of dispersing the microorganism-polymer complex. Polymers of formula (la) and of formula (lb).

Abstract: The present invention in general relates to the field of RNA purification methods. In particular, it relates to a method or reducing the dsRNA content of RNA samples, and accordingly increasing the ssRNA concentration in such samples. Said method is based on a filtration step performed on RNA samples containing ssRNA, dsRNA and at least one salt in the absence of cellulose.

Abstract: The present disclosure provides improved multiplex genome editing compositions and methods. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

Abstract: Provided herein are systems and methods for screening desirable biological variants using a high-throughput integrated system. The integrated system may be configured to input a plurality of parameters from functional studies of biological variants under applied conditions, in conjunction with integrated libraries of biological variants, and filter the inputs to produce desirable biological variants based on an input performance requirement. The system may output optimized strains, molecules, or novel molecules expected to have a desirable functional characteristic. Accordingly, the methods and systems disclosed herein enable multi-parametric studies of biological diversity and conditional diversity in systems biology.

Abstract: A barcoded transposase complex and an application thereof in high-throughput sequencing. Provided is a transposase recognition element, having the following structure: X(m)Y(f)N(n), in which X(m) represents a transposase recognition region of a double-stranded nucleic acid structure, Y(f) represents a spacer region of a single-stranded DNA structure, and N(n) represents a sample barcode of a single-stranded DNA structure. The high-molecular-weight DNA is processed using the barcoded transposase complex, to obtain a lot of barcoded DNA fragments. The barcoded DNA fragments obtained from each high-molecular-weight DNA are mixed to obtain a mixing sample. A carrier having a molecular barcode is adopted to capture. An exonuclease is adopted for processing, and then transposase is released. StLFR technology is adopted to construct a DNA library. The barcoded transposase complex can be applied to hybrid sequencing of a high-throughput sequencing platform.

Abstract: An imaging system having multiple cameras providing a large field of view with sufficient resolution can be used for tracking movements of cells from their positions in a tissue sample into multiple isolated areas such as into individual microwells in a well plate. By determining the beginning and the end of the movements of each cell, the imaging system can associate the microwell locations to the original cell positions in the sample. Together with an analysis of the cells in the microwells, either individually or together with barcode beads, the analysis can achieve the spatial information needed for constructing a map of the molecular information with respect to the positions of the cells in the sample.

Abstract: Described herein are compositions and methods for identifying, selecting, or culturing cells comprising a subject nucleic acid sequence of interest. Generally, a nucleic acid comprising a subject nucleic acid and a sequence encoding an enzyme molecule involved in biosynthesis of an amino acid is introduced into a cell. The cell is then grown on media lacking the amino acid, such that cells comprising the introduced nucleic acid are capable of growth. In some instances, the cell further comprises an inhibitor of the enzyme molecule to increase the stringency of the selection.

Abstract: The present application discloses methods useful for the multiplex measurement of enzymatic activities. Also disclosed are polynucleotide constructs, constructs libraries and compartments related suitable for use in the methods.

Abstract: Methods of generating cDNAs from RNA involving cleavage of DNA/RNA complexes are provided.

Abstract: RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1-3010 and compositions, methods, and uses thereof.

Abstract: Described herein are systems for targeting viral genomes. Also described herein are methods for targeting viral genomes utilizing the systems described in the instant disclosure. In some cases, systems and methods disclosed herein can be used to treat viral infections. In preferred embodiments, the systems utilise a CRISPR/Cas13d complex to target the genome of an RNA virus such as coronavirus or influenza virus.

Abstract: Provided herein are compositions and methods relating to providing or engineering a structural target to attract ADAT editing to a desired site. Further provided herein are compositions and methods relating to recombinant adenosine deaminase acting on tRNA (ADAT) guide tRNAs (adat-gtRNA). In certain embodiments, such compositions and methods will be useful for modifying a coding sequence of a desired protein. Also provided are methods of treating a disease or disorder associated with loss of wild-type protein expression.

Abstract: Disclosed herein are engineered guide RNAs, engineered polynucleotides, precursor engineered polynucleotide, vectors omprising engineered polynucleotide, nucleic acids of engineered polynucleotide, pharmaceutical compositions thereof, methods of making the engineered polynucleotides and methods of treating or preventing a disease or condition by administering above described thereof.

Abstract: The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

Abstract: Provided herein are antisense oligonucleotides and prophylactic and therapeutic methods featuring such oligonucleotides. These oligonucleotides and methods are useful for treating or preventing ataxia telangiectasia in a subject. Specifically, the disclosure provides antisense nucleobase oligomers each comprising (8-40) nucleobases, wherein at least 90% of said nucleobases or more than (8) consecutive nucleobases of the oligomer are complementary to a nucleic acid sequence in an Ataxia-Telangiectasia Mutated (ATM) allele comprising a mutation associated with aberrant splicing.

Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

Abstract: A double-stranded nucleic acid complex that can have an excellent activity is provided. In one embodiment, the present invention relates to a double-stranded nucleic acid complex having a first nucleic acid strand and a second nucleic acid strand. The first nucleic acid strand is capable of hybridizing to at least part of a target gene or a transcription thereof, has an antisense effect on the target gene or transcription product thereof, and has at least two morpholino nucleic acids The second nucleic acid strand has a base sequence complementary to the first nucleic acid strand. The first nucleic acid strand is annealed to the second nucleic acid strand.

Abstract: The present disclosure relates to engineered nucleic acids that target CAG repeat sequences or viral polynucleotides. The present disclosure also relates to the uses of the engineered nucleic acids for treating polyglutamine diseases or a viral infection.

Abstract: Provided is gRNA specifically targeting ?4GalNT2 gene. The gRNA specifically binds to the nucleotide sequence shown in any one of SEQ ID NOs. 1 and 2. Also provided are an animal model constructed using the gRNA, and an application thereof in the field of biomedicine.

Abstract: The present disclosure relates generally to compositions and methods suitable for treating a disorder associated with loss-of-function mutations in SYNGAP1. More specifically, the disclosure relates to methods for treating a disorder associated with heterozygous loss-of-function mutations of SYNGAP1, and to antisense oligonucleotides specific for SYNGAP1 and their use for treating a disorder associated with heterozygous loss-of-function mutations of SYNGAP1.

Abstract: The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.

Abstract: The invention provides a medication and a diagnostic kit for inhibiting metastasis and invasion of breast cancer, an shRNA molecule for silencing expression of human LINC01614 and applications thereof. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

Abstract: The compositions and methods provided herein are related, in part, to the discovery of cholic acid 7-sulfate as a treatment for diabetes. Selective transport of the microbial metabolite lithocholic acid (LCA) from the gut to the liver after bariatric surgery activates hepatic vitamin D receptor (VDR), thereby inducing expression of bile acid sulfotransferase SULT2A, which produces the antidiabetic molecule CA7S. Provided herein is a method for treating diabetes, obesity, or an inflammatory disease in a subject, the method comprises administering to a subject in need thereof a compound of Formula I-XV or Formula F-XV? or an agent that increases levels or activity or cholic acid 7-sulfate or upstream targets in a subject.

Abstract: The present invention relates to methods and compositions for editing an ABCA4 polynucleotide, e.g., an ABCA4 polynucleotide comprising a SNP associated with Stargardt Disease, type 1. The invention also relates to methods and compositions for treating or preventing Stargardt Disease, type 1, in a subject.

Abstract: The present disclosure relates to immunostimulatory compositions that are effective in eliciting immune responses in avian species.

Abstract: This disclosure relates to the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure relates to the technical field of fermentation of metabolically engineered microorganisms. This disclosure describes engineered micro-organisms that produce oligosaccharides that are free of KDO-lactose impurities and/or KDO-oligosaccharide impurities.

Abstract: The present disclosure provides ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing N-(7-((2S,4R,5R)-4-fluoro-3,3-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-4-oxo-4,7-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)isobutyramide. Also provided are polynucleotides encoding the ketoreductase enzymes, host cells capable of expressing the ketoreductase enzymes, and methods of using the ketoreductase enzymes to synthesize N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide.

Abstract: Described in this application are UDP-glycosyltransferases (UGT) enzymes, host cells expressing the UGTs, and methods of producing mogrol precursors, mogrol, and/or mogrosides using such host cells.

Abstract: Parkin protein variants having activating mutations and/or fused to a mitochondrial targeting sequence are provided. The engineered Parkin may be a fusion protein including a mitochondrial targeting sequence (MTS); a transmembrane domain; and a Parkin protein or functional variant or fragment thereof, such as a Parkin having an N-terminal deletion. The MTS may be the MTS of PINK1 or a functional variant thereof. Alternatively or in addition, the engineered Parkin may have one or more activating mutations, such as single amino-acid substitutions. The engineered Parkin may be delivered in a vector, such as an adeno-associated virus (AAV) vector, and may be used to treat a disease or disorder, such as Parkinson’s disease or any of various neurodegenerative diseases.